Company profilePharmaceutical#727 of 1,318 in Pakistan✓ No DRAP alerts

HOSPITAL SERVICES & SALES

Pharmaceutical company · 12 brands · 15 molecules

Ranked #3 of 17 companies in Vaccine

12 registered products 15 pharmaceutical brands 15 distinct molecules 0 DRAP alerts

Company overview

12
registered products
15
pharmaceutical brands
15
distinct molecules
3
therapeutic classes
0
DRAP alerts

HOSPITAL SERVICES & SALES is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 12 product registrations across 15 distinct molecules. Its portfolio is concentrated in Vaccine and Other Immunostimulating Agents. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by HOSPITAL

4 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

4
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
20251
20262
Longest without revision

Top molecules by brand count

Bcg Vaccine3 brands
Bacillus Calmette-Guerin1 brand
C (MENINGITIS VACCINE)1 brand
Y Vaccine1 brand
W1351 brand

Therapeutic classes

Vaccine · 8Other Immunostimulating Agents · 1Immune Sera And Immunoglobulins · 1

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

GSK Pakistan Limited5 shared molecules
SIND MEDICAL STORES3 shared molecules
NOVARTIS PHARMA (PAK) LTD2 shared molecules
IBL HEALTH CARE (PVT) LTD2 shared molecules
OBS Pharma (Pvt) Ltd2 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SANOFI AVENTIS (PAKISTAN) LTD. holds 75 molecules not in this portfolio
AlfuzosinAmilorideAmiodaroneAspirinAtorvastatinBacillus Clausii
GSK Pakistan Limited holds 20 molecules not in this portfolio
BacitracinBenzoyl PeroxideBetamethasoneClindamycinClindamycin TopicalClobetasol
Pfizer Laboratories (Pvt) Ltd. holds 132 molecules not in this portfolio
AlprazolamAluminium HydroxideAluminium Hydroxide And OxideAmlodipineAmodiaquineAmodiaquine Base

Get the full profile for HOSPITAL

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.